Introduction
============

Although the 6 minute walk test is simple and widely employed to assess submaximal exercise capacity and response to therapy in pulmonary arterial hypertension (PAH), it provides limited information.[@b1-ccrpm-2010-035] Maximal cardiopulmonary exercise testing (CPET) can provide more comprehensive physiologic information, but is less widely available, is subject to varying interpretation across centers, and may be inconvenient for patients to perform. Submaximal exercise gas exchange measurement, using simplified technology (ie, 'plug and play' systems),[@b2-ccrpm-2010-035] may be a simple alternative to formal CPET that could provide information beyond that available from a 6 minute walk.

Methods
=======

Three patients diagnosed with idiopathic pulmonary arterial hypertension were included in the present report. Each patient was seen twice in the PH clinic, with the visits separated by approximately 3--5 months. As part of their assessments standard clinical tests were performed, which included a transthoracic echo and 6 minute walk test, at both visits. In addition, submaximal exercise step tests were performed in conjunction with clinical tests, which consisted of 2 minutes rest, 3 minutes exercise and 1 minute recovery. Gas exchange was measured throughout using a SHAPE gas analysis system (SHAPE Medical Systems Inc, St. Paul, MN). The SHAPE system is a newly designed, small and portable gas analysis system that is self calibrating, containing built-in automated temperature, barometric pressure and humidity corrections. The interface is simplified and the software designed so that extensive understanding of the methodology and equipment is not required ([Fig. 1](#f1-ccrpm-2010-035){ref-type="fig"}).[@b2-ccrpm-2010-035]

Case Descriptions
=================

Patient A
---------

A 29 year old female evaluated for syncope was diagnosed with idiopathic PAH following right heart catheterization in December 2009. The pulmonary artery pressure at catheterization was 69/29 with a mean pulmonary arterial pressure (PAPm) of 45 mmHg, right atrial pressure (RAP) 5 mmHg, pulmonary wedge pressure (PCW) 5 mmHg, cardiac output (Q) 4.0 L/min, cardiac index (QI) 2.52 L/min/m^2^ and pulmonary vascular resistance (PVR) 10.0 Wood units. The patient was subsequently started on combination therapy, consisting of sildenafil (Revatio^®^) 20 mg tid and inhaled trepostinil sodium (TYVASO^®^) titrated to 9 breaths qid, and re-assessed approximately 3 months later.

Patient B
---------

A 56 year old female who was first diagnosed with idiopathic PAH in September 2004. It is possible she may have hereditary hemorrhagic telangiectasia based upon frequent nosebleeds but without other diagnostic features. Continuous prostanoids seemed contraindicated because of thrombocytopenia, and acquired Von Willebrands disease. Most recent right heart catheterization from June 2009 demonstrated a pulmonary artery pressure of 133/40 with a PAPm 78 mmHg, RAP 11 mmHg, PCW 10 mmHg, cardiac output 3.5 L/min with QI 2.09 L/min/m^2^ and PVR 19.6 Wood units. The patient had been on various therapeutic regimes but when seen in the PH clinic in February 2010 was functional class III on combination therapy, consisting of bosentan (Tracleer) 125 mg tid and iloprost (Ventavis) Solution for Nebulization 10 ug/1 ml by inhalation 6--7 times daily, and had been on this medication for approximately 2 years. The patient remained on the same therapy and returned for re-assessment 5 months later.

Patient C
---------

A 56 year old male was first diagnosed with PAH in 2005 in the context of prior splenectomy and was subsequently started on sildenafil (Revatio^®^) 20 mg tid in March 2006. The patient remained on this therapy until his visit to the PH clinic in March 2010, when the dose of sildenafil (Revatio^®^) was increased to 40 mg tid because the patient still had exercise limitations that impaired quality of life. Prior to the dose increase the patient had a right heart catheterization and had a pulmonary artery pressure of 78/21 with a PAPm 42 mmHg, RAP 8 mmHg, PCW 10 mmHg, Q 6.0 L/min, QI 2.7 L/min/m^2^ and PVR 5.3 Wood units. The patient was seen back, and re-tested, approximately 4 months later.

These cases are part of an on going study investigating gas exchange in PAH patients that has been reviewed and approved by the Mayo Institutional Review Board. Patient consent was obtained prior to testing.

Results
=======

Traditional clinical tests
--------------------------

Echocardiographic measurements and 6-minute walk distance are shown in [Table 1](#t1-ccrpm-2010-035){ref-type="table"}.

**Patient A** was free of recurrent syncope and was functional class III at follow up. The 6 minute walk increased from 357 m to 371 m after 3 months. Echocardiographic estimates of pulmonary artery pressure suggested improvement but were felt to be potentially unreliable due to minimal tricuspid regurgitation. There did appear to be improvement in right heart function as the tricuspid annular plane systolic excursion by M-mode \[TAPSE\] improved from 17 to 19 mm at 3 months. Right ventricular index of myocardial performance (RIMP) improved from 0.88 to 0.54 at 3 months, while there was no significant change in tricuspid lateral annulus systolic velocity (0.12 vs 0.11 m/sec).

**Patient B** remained functional class II--III. The 6-minute walk distance decreased slightly from 450 m to 436 m. Estimates of right ventricular pressure by echocardiography were felt to be potentially spuriously low due to trivial tricuspid regurgitation but was estimated at 65 and then 69 mmHg. Echocardiographic assessments of right ventricular function were equivocal, with tricuspid lateral annulus systolic velocity changing from 0.11 m/sec to 0.08 m/sec, RIMP 0.55 to 0.50, and TAPSE 10 mm to 12 mm. N terminal BNP decreased from 792 pg/ml to 547 pg/ml.

**Patient C** symptomatically felt improved but had very little change in RVSP or lateral annulus systolic velocity, which was within the normal range at baseline and follow up. There was however a large change in TAPSE, which increased from 21 to a supranormal value of 31 mm following 4 months of increased sildenafil treatment. Six-minute walk distance was decreased by ∼60 metres however despite this decrease the patient still achieved over 100% of age predicted distance (595 m). NBNP level was not available at the baseline assessment but was 100 pg/ml at time of followup, compatible with preserved right ventricular function.

Submaximal Exercise Gas Exchange
================================

**Patient A** had an improved end-tidal CO~2~ (P~ET~CO~2~) and breathing efficiency (V~E~/VCO~2~ slope/ratio), in accordance with improved heart function and walk distance, after 3-months treatment ([Fig. 2](#f2-ccrpm-2010-035){ref-type="fig"}). End-tidal CO~2~ was higher at rest and throughout exercise following treatment ([Fig. 2A](#f2-ccrpm-2010-035){ref-type="fig"}). A similar pattern was evident for breathing efficiency where the V~E~/VCO~2~ ratio was lower at rest and all points during exercise ([Fig. 2B](#f2-ccrpm-2010-035){ref-type="fig"}). In addition, the V~E~/VCO~2~ slope decreased favorably from 49, at baseline, to 43 ([Fig. 2C](#f2-ccrpm-2010-035){ref-type="fig"}).

**Patient B** had a reduced P~ET~CO~2~ and breathing efficiency at the time of 5 month follow up. End-tidal CO~2~ was lower at rest and during exercise ([Fig. 3A](#f3-ccrpm-2010-035){ref-type="fig"}) and V~E~/VCO~2~ ratio higher at all points. V~E~/VCO~2~ slope was therefore elevated from 37 at baseline to 45 ([Fig. 3C](#f3-ccrpm-2010-035){ref-type="fig"}).

**Patient C** demonstrated an improved P~ET~CO~2~ and breathing efficiency during exercise. This was despite an actual decrease in walk distance which may reflect the nonspecific nature of moderate changes in walk distance within this well preserved range. End tidal CO~2~ was similar at rest between the two conditions but differed during exercise ([Fig. 4A](#f4-ccrpm-2010-035){ref-type="fig"}). Whilst P~ET~CO~2~ remained constant at ∼28 mmHg during exercise at baseline, after 4 months of treatment P~ET~CO~2~ increased to 34 mmHg. V~E~/VCO~2~ ratio was lower at rest and throughout exercise ([Fig. 4B](#f4-ccrpm-2010-035){ref-type="fig"}) after treatment, as was V~E~/VCO~2~ slope ([Fig. 4C](#f4-ccrpm-2010-035){ref-type="fig"}), which decreased from 39 to 30.

Discussion
==========

Multiple parameters are currently utilized in an effort to track progress of patients with pulmonary arterial hypertension, and each of them has their strengths and weaknesses. Following a major shift in therapeutic approach such as occurred in patient A, we saw substantial improvement in multiple parameters including gas exchange variables. Patient B, with no fundamental change in treatment plan, had multiple parameters that were persistently abnormal but without consistent or major changes in direction. Worsening of submaximal gas exchange variables, P~ET~CO~2~ and V~E~/VCO~2~, was of concern but the significance of such changes needs to be further elucidated by serial follow up. Patient C was in a category of quite well preserved 6 minute walk distance and RV function where sensitivity of such methods for improvement in condition is limited. In fact he had little change in his right heart function/pressure by echo estimates aside from the increase in TAPSE, and a decrease in 6 minute walk distance. Gas exchange variables suggested there was an improved function following 4 months of therapy and appeared consistent with his impression of clinical improvement. It is possible that gas exchange variables, such as V~E~/VCO~2~, are more sensitive measures than other clinical measures and are able to better detect smaller changes earlier following treatment. Gas exchange data during submaximal exercise could, therefore, be a useful tool to track disease severity in PAH patients. Reduced pulmonary perfusion and V/Q (ventilatory/perfusion) mismatch is thought to be the most likely cause of alterations in breathing efficiency and endtidal CO~2~ levels in PAH.

Traditional clinical measures used to determine PAH severity and track patient responses to treatment are expensive, time consuming and require technical expertise (echocardiography) or lack sensitivity and ignore important aspects of disease (6 minute walk test).[@b1-ccrpm-2010-035] There is currently a need for more sophisticated endpoints that can be simply and inexpensively obtained. Recently it has been suggested that measuring gas exchange during exercise may be the answer, considering that one of the main symptoms of PAH is dyspnea. Submaximal CPET may be a more meaningful and specific endpoint measure that allows for the measurement of key variables (ie, physiological dead space, breathing efficiency and end-tidal CO~2~) that are likely to be affected by PAH. Recent research has described characteristic gas exchange abnormalities in PAH patients, including a high V~E~/VCO~2~ slope/ratio,[@b3-ccrpm-2010-035] a low resting P~ET~CO~2~ and decreased P~ET~CO~2~ during exercise.[@b4-ccrpm-2010-035] It has been suggested that these gas exchange variables track physiological changes in response to therapy.[@b5-ccrpm-2010-035] There is potential for developing algorithms, using multiple gas exchange variables (ie, V~E~/VCO~2~, P~ET~CO~2~ and other parameters), that may allow a more sophisticated and sensitive, yet simple, way to track disease status. More work is clearly required in this area to determine which parameters should be used and also to standardize testing so that there is uniformity in clinical practice.

Conclusion
==========

These cases demonstrate the potential utility of measuring submaximal exercise gas exchange to track responses to therapies in PAH patients. This will need to be evaluated and validated in a study of multiple PAH patients before its potential role in a clinical setting and as an endpoint measure can be fully understood.
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CPET

:   cardiopulmonary exercise testings

PAH

:   pulmonary arterial hypertension

PAPm

:   mean pulmonary artery pressure

PCW

:   pulmonary wedge pressure

P~ET~CO~2~

:   end tidal CO~2~

PVR

:   pulmonary vascular resistance

Q

:   cardiac output

QI

:   cardiac index

RAP

:   right atrial pressure

RVSP

:   right ventricle systolic pressure

TAPSE

:   tricuspid annular plane systolic excursion by M-mode echocardiography

V~E~/VCO~2~

:   ratio of minute ventilation to expired carbon dioxide (a measure of breathing efficiency)

V/Q

:   ventilation/perfusion

![A SHAPE system which consists of a gas analyser, laptop, mouthpiece and pneumotach appliance and finger pulse oximeter.](ccrpm-2010-035f1){#f1-ccrpm-2010-035}

![Patient A: Gas exchange variables at rest and during exercise at baseline (circle) and 3-months following treatment (square). Data is presented for P~ET~CO~2~ (**A**), V~E~/VCO~2~ ratio (**B**) and V~E~/VCO~2~ slope (**C**).](ccrpm-2010-035f2){#f2-ccrpm-2010-035}

![Patient B: Gas exchange variables at rest and during exercise at baseline (circle) and 5-months following treatment (square). Data is presented for P~ET~CO~2~ (**A**), V~E~/VCO~2~ ratio (**B**) and V~E~/VCO~2~ slope (**C**).](ccrpm-2010-035f3){#f3-ccrpm-2010-035}

![Patient C: Gas exchange variables at rest and during exercise at baseline (circle) and 4-months following treatment (square). Data is presented for P~ET~CO~2~ (**A**), V~E~/VCO~2~ ratio (**B**) and V~E~/VCO~2~ slope (**C**).](ccrpm-2010-035f4){#f4-ccrpm-2010-035}

###### 

Routine clinical measures used to assess pulmonary hypertension severity.

                                              **Patient A**   **Patient B**   **Patient C**                   
  ------------------------------------------- --------------- --------------- --------------- ------- ------- -------
  *Echocardiography*                                                                                          
  RVSP (mmHg)                                 49              43              65              69      66      68
  TAPSE (mm)                                  17              19              na              12      21      31
  Lateral annulus systolic velocity (m/sec)   0.12            0.11            0.11            0.08    0.14    0.14
  Cardiac index (l/min/m^2^)                  2.46            2.66            3.04            3       2.48    3.15
  *6 minute walk*                                                                                             
  Distance (m)                                356             370             449.9           436.2   660.3   594.8
  \% predicted                                50              52              87              84      116     104

**Abbreviations:** RVSP, estimated right ventricle systolic pressure; TAPSE, tricuspid annular plane systolic excursion by M-mode.
